Drug profile · INN
dapiprazole hydrochloride
DAPIPRAZOLE HYDROCHLORIDE
dapiprazole hydrochloride (DAPIPRAZOLE HYDROCHLORIDE) is a alpha-1a adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — dapiprazole hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dapiprazole hydrochloride (DAPIPRAZOLE HYDROCHLORIDE) is a alpha-1a adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Alpha-1a adrenergic receptor antagonist
Primary target: Alpha-1A adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dapiprazole hydrochloride?
dapiprazole hydrochloride (DAPIPRAZOLE HYDROCHLORIDE) is a alpha-1a adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for dapiprazole hydrochloride?
DAPIPRAZOLE HYDROCHLORIDE is a marketed brand name for dapiprazole hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dapiprazole hydrochloride?
dapiprazole hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.